Arcturus Therapeutics is a messenger RNA (mRNA) medicines company developing therapies for rare genetic disorders and commercial vaccines. Its core therapeutic pipeline includes ARCT-032 for cystic fibrosis and ARCT-810 for ornithine transcarbamylase deficiency, both delivered via its proprietary LUNAR lipid-mediated delivery platform; the company also commercializes KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine approved in multiple markets and sold through partners like Meiji Seika Pharma in Japan, alongside a vaccine pipeline encompassing influenza and pandemic preparedness candidates. Arcturus generates revenue through milestone payments and royalties on therapeutic commercialization, direct vaccine sales, development funding from government partners and disease foundations, and profit-share agreements with large vaccine manufacturers such as CSL Seqirus, which has exclusive rights to develop and commercialize most of the company's vaccine candidates globally.